Skip to content
ESPT
MARKETS / BALCAO / Health care / Pharmaceuticals / BSPK
BALCAO · PHARMACEUTICAL PREPARATIONS

Bespoke Extracts, Inc. BSPK

14 fiscal years on record · USD · FY2024 reported · SEC filings only
$1.1M
▲ 42.3% YoY
$-1.0M
$-889,802

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

The Company has one wholly-owned subsidiary, Bespoke Extracts Colorado, LLC (“Bespoke Colorado”). Currently, Bespoke owns, manufactures, and distributes a portfolio of cannabis consumer packaged goods brands including Fresh Joints, Doobskis, DutchBlunts, and Wee Joints, to licensed marijuana dispensaries across Colorado. Since the change in management and control of the Company that occurred in November 2021, we now primarily operate within the regulated cannabis industry through Bespoke Colorado. We are a licensed operator in the recreational adult-use cannabis market in Colorado where we offer, and plan to expand, a portfolio of adult-use brands and products. As of the date of the filing of this report, we have 8 full-time employees.

Written from the business description in Bespoke Extracts, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 21 April 2025. Every sentence was checked against that document before publication.

Growth

USD 1.1M
Revenue, FY2024 · full 14-year series below
Revenue $M Net income $M
FY2024 · Revenue 1.1 · Net income -1.0
1M2M-3M-6M
201120142017202020232024
Compound annual growth
+215.5%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2022 · Operating -118011.6%
-50000%-100000%
201120172024
ROE
FY2015 · ROE -142.9%
-100%-200%
201120172024
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.
Gross margin·
Operating margin·
Net margin·
EBITDAUSD -984,991.00

Cash & shareholders

·
returned in FY2024 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -0.9
-0.5M-1.0M
201120172024
Net buybacks $ Dividends $
FY2020 · Dividends · · Net buybacks 27500.0
1000020000
2020
Dividends paid·
Net buybacks·
Share of profit·
Consecutive raises·

Total assetsUSD 359,088.00
EquityUSD -2.1M
CashUSD 60,305.00
Gross debtUSD 310,000.00
Net debtUSD 249,695.00
Current ratio0.15×

Equity was zero or negative — liabilities equaled or exceeded assets. No ratio is shown.

The 14-year record

14 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
BSPK, 14-year financial record
Metric 20242023202220212020201920182017201620152014201320122011
Revenue $B0.00.00.00.0◌0.00.0◌◌◌◌◌◌◌
Operating income $B−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0◌◌◌◌◌◌◌◌◌◌◌◌
Income tax $B◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0◌−0.0−0.0◌◌◌◌◌◌◌◌◌◌
EPS, diluted $−0.10−0.15−0.44−0.19−0.040.04−0.21−0.48−0.13−0.30−0.25−0.090.000.00
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————————
ROE %—————————−142.9−54.8−45.8−94.5−248.7
Shares out B0.010.010.010.250.190.080.040.030.000.000.010.010.330.34

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 60 reconciliationsAUDITED

Reconciled in 14 of the 14 fiscal years we could check. 11 checks were skipped: revenue is not tagged before 2018. Eight checks were skipped: the balance sheet is not tagged before 2011. Four checks were skipped: EPS is not tagged before 2011.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inNevada
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2011

Share this section

Download image